Glypican-3-targeted 89zr PEt imaging of hepatocellular carcinoma

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 799-804

  Sham, Jonathan G ^a   Kievit, Forrest M ^b   Grierson, John R ^a   Miyaoka, Robert S ^a   Yeh, Matthew M ^b   Zhang, Miqin ^c   Yeung, Raymond S ^a   Minoshima, Satoshi ^a   Park, James O ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Washington   (United States)

Author keywords

89Zr; Glypican 3; Hepatocellular carcinoma; Liver; PET

Indexed keywords

GLYPICAN 3; MESSENGER RNA; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM ALPHA GLYPICAN 3 ZR 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; GENE OVEREXPRESSION; GLYPICAN 3 GENE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR VOLUME;

89ZR; GLYPICAN 3; HEPATOCELLULAR CARCINOMA; LIVER; PET;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HEP G2 CELLS; HUMANS; LAMININ; LIVER; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEOGLYCANS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RNA, MESSENGER; TISSUE DISTRIBUTION; ZIRCONIUM;

EID: 84901366021     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.132118     Document Type: Article

References (39)

1. Ferenci P, Fried M, Labrecque D, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239-245.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer website. http://globocan.iarc.fr. Accessed March 6, 2014.
3. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
4. Ayyappan AP, Jhaveri KS. CT and MRI of hepatocellular carcinoma: an update. Expert Rev Anticancer Ther. 2010;10:507-519.
5. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut. 2010;59:638-644.
6. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma. Am J Gastroenterol. 2006;101:513-523.
7. Golfieri R, Marini E, Bazzocchi A, et al. Small (,or53 cm) hepatocellular carcinoma in cirrhosis: the role of double contrast agents in MR imaging vs. multidetector-row CT. Radiol Med (Torino). 2009;114:1239-1266.
8. Saborido BP, Diaz JC, de Los Galanes SJ, et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc. 2005;37:3874-3877.
9. SilvaMA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer. Gut. 2008;57:1592-1596.
10. Hayashi PH, Trotter JF, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl. 2004;10:42-48.
11. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009; 373:614-616.
12. Lu X, Zhao H, Yang H, et al. A prospective clinical study on early recurrence of hepatocellular carcinoma after hepatectomy. J Surg Oncol. 2009;100:488-493.
13. Kaur S, Venktaraman G, Jain M, Senapati S, Garg PK, Batra SK. Recent trends in antibody-based oncologic imaging. Cancer Lett. 2012;315:97-111.
14. Zhang Y, Hong H, Cai W. PET tracers based on zirconium-89. Curr Radiopharm. 2011;4:131-139.
15. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
16. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med. 2012;53:113-120.
17. Ruggiero A, Holland JP, Hudolin T, et al. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med. 2011;52:1608-1615.
18. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50:1116-1123.
19. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J Nucl Med. 2010;51:942-950.
20. Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW. HER1-targeted 86Ypanitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE. 2011;6:e18198.
21. Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2011;47:333-338.
22. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247.
23. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57:5179-5184.
24. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97.
25. Jia HL, Ye QH, Qin LX, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133-1139.
26. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16-25.
27. Park JO, Stephen Z, Sun C, et al. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Mol Imaging. 2011;10:69-77.
28. Wayner EA, Hoffstrom BG. Development of monoclonal antibodies to integrin receptors. Methods Enzymol. 2007;426:117-153.
29. Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5:739-743.
30. Gage GJ, Kipke DR, Shain W. Whole animal perfusion fixation for rodents. J Vis Exp. 2012:e3564.
31. Schaefer JV, Pluckthun A. Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel. 2012;25:485-506.
32. De Cat B, David G. Developmental roles of the glypicans. Semin Cell Dev Biol. 2001;12:117-125.
33. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol. 2008;9:224.
34. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001; 108:497-501.
35. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
36. MajmudarMD, Yoo J, Keliher EJ, et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res. 2013;112:755-761.
37. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012;18:1586-1591.
38. Janjigian YY, Viola-Villegas N, Holland JP, et al. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J NuclMed. 2013;54:936-943.
39. Börjesson PKE, Jauw YWS, de Bree R, et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.